Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

La evaluación del fármaco R3R01 para la excreción de proteínas en la orina en pacientes con enfermedad renal diabética. (Kidney ABC)

18 de septiembre de 2026 actualizado por: River 3 Renal Corp.

Efectos del inductor ABCA1 R3R01 sobre los niveles de albuminuria en la enfermedad renal diabética

The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease.

The main questions it aims to answer are:

  1. Does 3 months of treatment with 200mg of the drug R3R01 morning and evening have a beneficial effect on the amount of protein excreted in the urine in patients with type 2 diabetes and kidney disease?
  2. Does R3R01 have an effect on kidney function and daily blood pressure?

Researchers will compare the results of 40 people who take R3R01 to 20 people who receive an inactive substance (placebo).

Participants will receive R3R01 or the placebo as an oral tablet and undergo a selection of medical examinations - such as:

  • blood samples
  • urine tests
  • kidney tests involving a radiolabelled marker which is injected into the bloodstream and monitored via blood samples
  • 24 hour blood pressure monitoring via a wearable device
  • urine pregnancy test (if applicable)

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

An increasing amount of evidence suggests that lipid dysmetabolism and accumulation in the kidneys play a central role in the pathogenesis of kidney disease. This lipotoxicity, in turn, may contribute to the development of albuminuria and chronic kidney disease.

One may surmise that interventions that reduce or prevent the progression of kidney lipid accumulation protect against the progression of kidney disease, including diabetic kidney disease (DKD). Therefore, it is possible inhibiting cholesterol absorption, might effectively protect against lipid accumulation and related disease in the kidneys.

R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney.

Persons with type 2 diabetes with moderate and severe albuminuria have a poor renal and cardiovascular prognosis. As albuminuria is viewed both as a risk marker but also as a target for intervention, any treatment with antiproteinuric effects could be beneficial. The role of ABCA1 inducer treatment on kidney parameters in diabetic kidney disease is not known. By investigating the impact of ABCA1 inducer treatment on albuminuria, it will be determined whether this intervention may represent a future treatment option.

This study is a single center, double-blind, placebo controlled, parallel group randomized (2:1) study, in 60 people with type 2 diabetes with moderate or severe albuminuria and estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73m2. 40 people will take R3R01 whilst 20 people receive the placebo.

The study's primary objective is to evaluate the effect of 12 weeks treatment with R3R01 on albuminuria in the study population. In addition to a 12 week treatment period, there will be a follow-up period of approximately 24 weeks (168 days). The expected total duration of study participation is up to 36 weeks for each patient.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Copenhagen
      • Copenhagen, Copenhagen, Dinamarca, 2730
        • Reclutamiento
        • Steno Diabetes Center Copenhagen
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Adults (above 18 years of age) with controlled type 2 diabetes (hemoglobin A1c less than 10.5%).
  2. Stable antihypertensive treatment 4 weeks before start of study drug and throughout study duration.
  3. Titrated to the maximal dose or maximal tolerated dose of renin-angiotensin blocking treatment.
  4. Stable treatment with lipid lowering agents for at least 4 weeks.
  5. People on SGLT2-Inhibitors should be on a stable dose of the drug for at least 3 months.
  6. UACR >30 mg/g and < 5000 mg/g on two consecutive measurements.
  7. eGFR >30 ml/min/1.73 m2 (CKD-EPIcrea formula).
  8. Abdominal obesity Women: > 80 cm, Men: > 95 cm or fasting triglyceride >2.0 mmol/l.
  9. Systolic blood pressure ≥110 mmHg and ≤160 mmHg.
  10. Both female patients, as well as female partners of male patients who are of child-bearing potential must be willing to not become pregnant for the complete duration of the study and 90 days after the last dose of study medication.
  11. Males (including sterilized subjects) whose female partners have child-bearing potential, must agree to use male contraception (condoms) during the period from the time of signing the informed consent form through 90 days after the last dose of study drug. They must agree to immediately inform the investigator if their partner becomes pregnant during the study.

Exclusion Criteria:

  1. Polycystic kidney disease, ANCA-associated vasculitis, or lupus nephritis.
  2. Ongoing cancer treatment.
  3. Immunosuppressive therapy or immunosuppression the prior 6 months.
  4. Nephrotic syndrome.
  5. Impaired liver function (clinically significant).
  6. Pregnancy or lactation.
  7. Failure to understand patient information or to collaborate with the investigator.
  8. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study unless they agree to use highly effective contraception.
  9. History of hypersensitivity to study drug and/or any of its excipients.
  10. Hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
  11. Active or planned treatment with a medication that interacts with R3R01.
  12. Any other medical condition(s) that might put the patient at risk or influence study results in the investigators opinion, or that the investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: R3R01

R3R01 oral tablet (200 mg twice daily) for 12 weeks

R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.

Comparador de placebos: Placebo

Placebo oral tablet twice daily for 12 weeks

Please refer to arm/group description for further information.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Urinary albumin-to-creatinine ratio (UACR)
Periodo de tiempo: 12 weeks (84 days)

Urinary albumin-to-creatinine ratio (UACR) (Change from baseline to end of treatment at 12 weeks (84 days).

12 weeks (84 days)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Measured or Estimated Glomerular Filtration Rate
Periodo de tiempo: 12 weeks (84 days)

Measured glomerular filtration rate (GFR) with plasma clearance of 99Tc-DTPA or eGFR measured with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on creatinine and/or cystatin C (change from baseline to end of treatment at 12 weeks (84 days)).

12 weeks (84 days)
24 hours ambulatory blood pressure
Periodo de tiempo: 12 weeks (84 days)

24 hours ambulatory blood pressure (change from baseline to end of treatment at 12 weeks (84 days)).

12 weeks (84 days)
Plasma Pharmacokinetics
Periodo de tiempo: 24 weeks (168 days)

R3R01 plasma concentrations will be measured to determine Maximum plasma concentration (Cmax)

24 weeks (168 days)
Plasma Pharmacokinetics
Periodo de tiempo: 24 weeks (168 days)

R3R01 plasma concentrations will be measured to determine minimum blood plasma concentration (Cmin)

24 weeks (168 days)
Plasma Pharmacokinetics
Periodo de tiempo: 24 weeks (168 days)

R3R01 plasma concentrations will be measured to determine the half-life (T1/2)

24 weeks (168 days)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Peter Rossing, dr.med., Steno Diabetes Center Copenhagen

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de octubre de 2024

Finalización primaria (Estimado)

1 de abril de 2027

Finalización del estudio (Estimado)

1 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de septiembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

13 de septiembre de 2024

Publicado por primera vez (Actual)

19 de septiembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir